Pharmacokinetic characteristics of allitinib and its major metabolites following the oral administration of 1,000 mg of allitinib tosylate three times a day for 21 days in cancer patients
All values are mean ± S.D.
| Time | Parameter | Allitinib | M6 | M10 |
|---|---|---|---|---|
| Day 1 | AUC0–24 (h·ng/ml) | 529 ± 185 | 65.7 ± 39.6 | 372 ± 65 |
| Cmax (ng/ml) | 56.8 ± 17.1 | 5.97 ± 3.70 | 35.8 ± 5.0 | |
| tmax (h) | 3.56 ± 2.65 | 5.17 ± 2.47 | 4.50 ± 2.72 | |
| t1/2 (h) | 6.30 ± 3.08 | 10.0 ± 4.2 | 7.07 ± 3.93 | |
| Day 24 | AUC0–24 (h·ng/ml) | 933 ± 407 | 92.0 ± 36.0 | 699 ± 415 |
| Cmax (ng/ml) | 111 ± 35 | 6.21 ± 2.92 | 59.9 ± 37.7 | |
| tmax (h) | 2.83 ± 2.15 | 2.50 ± 1.00 | 3.16 ± 1.60 | |
| t1/2 (h) | 6.61 ± 1.76 | 13.5 ± 2.9 | 7.28 ± 0.54 | |
| Accumulation ratio | 1.76 ± 0.33 | 1.70 ± 0.94 | 1.78 ± 0.91 |
Cmax, maximum concentration observed in day 1 or day 24 after administration of allitinib tosylate; tmax, time to the maximum concentration.